UroGen Pharma Ltd (URGN)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Elizabeth Barrett
Employees:
200
9 HA'TA'ASIYA ST, RA'ANANA, ISRAEL 4365007
972 9 770 7601

UroGen Pharma Ltd. engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs. The company's lead product candidate is UGN-102, which is in Phase III clinical trials.

Data derived from most recent annual or quarterly report
Market Cap 370.803 Million Shares Outstanding23.454 Million Avg 30-day Volume 197.201 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.18
Price to Revenue4.3219 Debt to Equity-0.7101 EBITDA-93.734 Million
Price to Book Value0.0 Operating Margin-104.51740000000001 Enterprise Value355.413 Million
Current Ratio3.039 EPS Growth0 Quick Ratio2.347
1 Yr BETA 0.1851 52-week High/Low 24.13 / 7.08 Profit Margin-150.3709
Operating Cash Flow Growth1.4941 Free Cash Flow to Firm (FCFF) TTM -39.77 Million Free Cash Flow to Equity (FCFE) TTM-28.271 Million
Altman Z-Score-10.3501
Earnings Report2023-11-09
View SEC Filings from URGN instead.

View recent insider trading info

UroGen Pharma Ltd YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding URGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding URGN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-08 by WILDMAN DANIEL GEORGE
  • 4: filed on 2023-09-08 by HOLDEN STUART
  • 4: filed on 2023-09-08 by ROBINSON JAMES A. JR.
  • 4: filed on 2023-09-08 by WEN LEANA
  • 4: filed on 2023-09-08 by SMITH JASON DREW
  • 4: filed on 2023-09-08 by KIM DONG
  • 4: filed on 2023-09-08 by SCHOENBERG MARK
  • 4: filed on 2023-09-05 by SMITH JASON DREW
  • 4/A: filed on 2023-07-28 by ROBINSON JAMES A. JR.
  • 4: filed on 2023-07-27 by ROBINSON JAMES A. JR.

    • Events (8k)

  • 8-K: filed on 2023-09-11:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-25:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-22:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-10-21:
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2022-09-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    3.8 Thousand total shares from 1 transactions

    Exercise Derivative Conversion (M)

    8.3 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BUTITTA CYNTHIA M

    • Director
    		 0 2023-09-07 1

    BELLDEGRUN ARIE

    • Director
    		 0 2023-09-07 1

    COHEN FRED E

    • Director
    		 0 2023-09-07 2

    ROBINSON JAMES A. JR.

    • Director
    		 0 2023-09-07 4

    SCHOENBERG MARK CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-09-07 5

    HOLDEN STUART

    • Director
    		 0 2023-09-07 1

    SMITH JASON DREW GENERAL COUNSEL

    • Officer
    		 0 2023-09-07 3

    WEN LEANA

    • Director
    		 0 2023-09-07 1

    KIM DONG CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-09-07 2

    WILDMAN DANIEL GEORGE

    • Director
    		 0 2023-09-07 3

    BARRETT ELIZABETH A. CHIEF EXECUTIVE OFFICER

    • Officer
    		 326,691 2023-01-31 1

    NUSSBAUM RAN

    • Director
    		 1,481,927 2022-10-21 2

    HENDERSON MOLLY CHIEF FINANCIAL OFFICER

    • Officer
    		 44,082 2022-01-31 0

    FALBERG KATHRYN E

    • Director
    		 10,000 2021-06-07 0

    TOMASELLO SHAWN

    • Director
    		 10,000 2021-06-07 0

    PFREUNDSCHUH PETER P. CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2020-10-15 0

    MULLENNIX STEPHEN CHIEF OPERATING OFFICER

    • Officer
    		 10,084 2020-04-26 0

    BENTSUR RON CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 38,113 2019-01-01 0

    PROQUEST INVESTMENTS IV, L.P.

    PROQUEST ASSOCIATES IV LLC

    MOORIN JAY

    SCHREIBER ALAIN

    • 10% Owner
    		 No longer subject to file 2017-11-27 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SCHOENBERG MARK - Officer CHIEF MEDICAL OFFICER

    		2023-09-08 15:40:34 -0400 2023-09-07 A 5,000 a 5,000 direct

    KIM DONG - Officer CHIEF FINANCIAL OFFICER

    		2023-09-08 15:41:07 -0400 2023-09-07 A 7,500 a 7,500 direct

    WEN LEANA - Director

    		2023-09-08 15:41:47 -0400 2023-09-07 A 10,000 a 10,000 direct

    SMITH JASON DREW - Officer GENERAL COUNSEL

    		2023-09-08 15:41:21 -0400 2023-09-07 A 10,000 a 10,000 direct

    HOLDEN STUART - Director

    		2023-09-08 15:42:15 -0400 2023-09-07 A 10,000 a 10,000 direct

    ROBINSON JAMES A. JR. - Director

    		2023-09-08 15:41:58 -0400 2023-09-07 A 10,000 a 10,000 direct

    WILDMAN DANIEL GEORGE - Director

    		2023-09-08 15:42:44 -0400 2023-09-07 A 10,000 a 10,000 direct

    BUTITTA CYNTHIA M - Director

    		2023-09-08 15:43:15 -0400 2023-09-07 A 10,000 a 10,000 direct

    COHEN FRED E - Director

    		2023-09-08 15:42:56 -0400 2023-09-07 A 10,000 a 10,000 direct

    BELLDEGRUN ARIE - Director

    		2023-09-08 15:43:29 -0400 2023-09-07 A 10,000 a 10,000 direct

    SMITH JASON DREW - Officer GENERAL COUNSEL

    		2023-09-05 16:28:18 -0400 2023-08-31 S 3,800 $18.01 d 18,407 direct -6.0758 -12.709 0.0 1 -12.709 6

    SMITH JASON DREW - Officer GENERAL COUNSEL

    		2023-09-05 16:28:18 -0400 2023-08-31 M 8,334 a 22,207 direct -6.0758 -12.709 0.0 1 -12.709 6

    SMITH JASON DREW - Officer GENERAL COUNSEL

    		2023-09-05 16:28:18 -0400 2023-08-31 M 8,334 d 0 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    UROGEN PHARMA LTD URGN 2023-09-26 13:45:03 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-26 13:15:03 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-26 12:45:05 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 22:15:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 21:45:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 21:15:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 20:45:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 20:15:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 19:45:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 19:15:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 18:45:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 18:15:03 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 17:45:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 17:15:03 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 16:45:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 16:15:03 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 15:45:03 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 15:15:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 14:45:04 UTC -0.0211 5.3411 300000
    UROGEN PHARMA LTD URGN 2023-09-25 14:15:04 UTC -0.0211 5.3411 300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund URGN -4.0 shares, $-71.36 2020-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund URGN -100.0 shares, $-1035.0 2023-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments